Concord Drugs Ltd
BSE:538965
Cash Flow Statement
Cash Flow Statement
Concord Drugs Ltd
| Mar-2020 | Sep-2020 | Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||
| Net Income |
5
|
5
|
43
|
56
|
22
|
11
|
12
|
22
|
6
|
(7)
|
7
|
|
| Depreciation & Amortization |
15
|
21
|
14
|
18
|
18
|
16
|
16
|
15
|
16
|
15
|
14
|
|
| Other Non-Cash Items |
14
|
23
|
12
|
15
|
14
|
10
|
16
|
18
|
19
|
19
|
20
|
|
| Cash Taxes Paid |
1
|
2
|
5
|
9
|
7
|
3
|
4
|
6
|
2
|
(1)
|
2
|
|
| Cash Interest Paid |
14
|
23
|
12
|
15
|
14
|
10
|
16
|
18
|
19
|
19
|
20
|
|
| Change in Working Capital |
(9)
|
(9)
|
(53)
|
(47)
|
(46)
|
(71)
|
(28)
|
(42)
|
(33)
|
(32)
|
(4)
|
|
| Cash from Operating Activities |
25
N/A
|
39
+56%
|
16
-58%
|
42
+159%
|
8
-82%
|
(33)
N/A
|
17
N/A
|
12
-25%
|
8
-36%
|
(5)
N/A
|
37
N/A
|
|
| Investing Cash Flow | ||||||||||||
| Capital Expenditures |
(8)
|
(19)
|
(37)
|
(36)
|
(0)
|
7
|
(9)
|
(7)
|
(10)
|
(10)
|
(23)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
(14)
|
(14)
|
0
|
0
|
0
|
|
| Cash from Investing Activities |
(8)
N/A
|
(19)
-128%
|
(37)
-91%
|
(36)
+1%
|
0
N/A
|
7
+5 978%
|
(23)
N/A
|
(21)
+5%
|
(10)
+53%
|
(10)
0%
|
(23)
-129%
|
|
| Financing Cash Flow | ||||||||||||
| Net Issuance of Common Stock |
9
|
9
|
0
|
0
|
0
|
0
|
19
|
19
|
7
|
0
|
0
|
|
| Net Issuance of Debt |
(3)
|
41
|
34
|
(28)
|
35
|
64
|
(2)
|
(1)
|
5
|
17
|
6
|
|
| Other |
(24)
|
(29)
|
(13)
|
(16)
|
(18)
|
(14)
|
(11)
|
(8)
|
(9)
|
(13)
|
(20)
|
|
| Cash from Financing Activities |
(18)
N/A
|
20
N/A
|
21
+3%
|
(44)
N/A
|
17
N/A
|
51
+203%
|
6
-88%
|
10
+62%
|
3
-72%
|
11
+288%
|
(14)
N/A
|
|
| Change in Cash | ||||||||||||
| Net Change in Cash |
(1)
N/A
|
40
N/A
|
0
-99%
|
(39)
N/A
|
25
N/A
|
25
+2%
|
0
-99%
|
1
+418%
|
1
-40%
|
(4)
N/A
|
(0)
+94%
|
|
| Free Cash Flow | ||||||||||||
| Free Cash Flow |
16
N/A
|
20
+19%
|
(21)
N/A
|
5
N/A
|
8
+43%
|
(26)
N/A
|
8
N/A
|
5
-36%
|
(2)
N/A
|
(15)
-577%
|
14
N/A
|
|